Correlation between Lipoprotein(a) and Endometrial Cancer Prognosis: a Retrospective Cohort Study

Area of Science:

• Gynecological Oncology
• Cardiovascular Biomarkers
• Cancer Prognostics

Background:

• Endometrial cancer (EC) is a common gynecological malignancy with increasing incidence worldwide.
• Metabolic factors like lipid profiles and hyperglycemia are implicated in EC pathogenesis.
• The prognostic role of lipoprotein(a) [Lp(a)] in EC remains under-explored.

Purpose of the Study:

• To investigate the association between lipoprotein(a) [Lp(a)] levels and prognosis in patients diagnosed with endometrial cancer (EC).
• To determine if Lp(a) can serve as a predictive biomarker for EC outcomes.

Main Methods:

• Retrospective cohort study of 296 EC patients diagnosed between January 2017 and January 2022.
• Measurement of serum Lp(a) concentrations post-admission.
• Multivariate logistic regression analysis to assess the relationship between Lp(a) levels and EC prognosis (favorable vs. poor).

Main Results:

• A favorable prognosis (no recurrence within five years) was observed in 72.3% of EC patients.
• Patients with higher Lp(a) levels (Q2 > 122.2 g/L) showed a lower favorable prognosis rate (66.9%) compared to those with lower levels (Q1 ≤ 122.2 g/L, 77.7%), with statistical significance (p < 0.05).
• Multivariate analysis indicated that elevated Lp(a) levels were significantly associated with poorer EC prognosis (ORs ranging from 1.72 to 2.04).

Conclusions:

• Lipoprotein(a) [Lp(a)] is significantly associated with endometrial cancer (EC) prognosis.
• Lp(a) demonstrates potential as a clinical prognostic marker for EC.
• Further research is recommended to validate these findings and explore clinical applications.